证券代码：301263 证券简称：泰恩康 公告编号：2025-049 广东泰恩康医药股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 广东泰恩康医药股份有限公司（以下简称"公司"）第五届董事会第九次 会议（以下简称"会议"）通知于 2025 年 7 月 31 日以书面送达或电子邮件方 式向全体董事发出，会议于 2025 年 8 月 4 日在公司会议室以通讯会议的方式召 开。会议由董事长郑汉杰先生召集主持，应出席董事 7 人，实际出席董事 7 人，全部监事和高级管理人员列席会议。 本次董事会会议召集、召开符合《中华人民共和国公司法》（以下简称 "《公司法》"）《广东泰恩康医药股份有限公司章程》（以下简称《公司章 程》）等的规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于 <广东泰恩康医药股份有限公司 ensp="ensp" 年员工持股计="年员工持股计"> 划（草案）>及其摘要的议案》 为了建立和完善劳动者与所有者的利益共享机制，进一步改善公司治理水 平，提 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-050 广东泰恩康医药股份有限公司 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 广东泰恩康医药股份有限公司（以下简称"公司"）第五届监事会第九次会 议（以下简称"会议"）通知于 2025 年 7 月 31 日以电子邮件方式向全体监事发 出，会议于 2025 年 8 月 4 日以通讯表决方式召开。会议由监事会主席林姿丽女 士召集主持，应出席监事 3 人，实际出席监事 3 人。 本次监事会会议召集、召开符合《中华人民共和国公司法》 （以下简称"《公 司法》 经与会监事充分讨论，本次会议审议通过议案如下： （一）审议《关于 <广东泰恩康医药股份有限公司 ensp="ensp" 年员工持股计划="年员工持股计划" 草 ="草"> 案）>及其摘要的议案》 为了建立和完善劳动者与所有者的利益共享机制，进一步改善公司治理水平， 提高职工的凝聚力和公司竞争力，促进公司长期、持续、健康发展，充分调动公 司员工对公司的责任意识，根据《公司法》 《中华人民共和国证券法》 《关于上市 公司实施员工 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-051 广东泰恩康医药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》及《广东泰恩康医药股份有限公司章程》 （以 下简称"《公司章程》"）的规定，广东泰恩康医药股份有限公司（以下简称"公 司"）于 2025 年 8 月 4 日召开第五届董事会第九次会议审议通过《关于召开公司 召开 2025 年第一次临时股东大会。现将本次会议有关事项通知如下： 一、召开会议的基本情况 （1）公司第五届董事会第九次会议于 2025 年 8 月 4 日召开，审议通过《关 于召开公司 2025 年第一次临时股东大会的议案》。 （2）本次股东大会会议召集程序符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定。 （1）现场会议时间：2025 年 8 月 20 日（星期三）下午 15:00。 （2）网络投票时间：其中，通过深圳证券交易所（以下简称"深交所"） 交易系统进行网络投票的具体时间为：2025 年 8 月 20 日 9:15-9:25、9:30-11:30， （1 ...

Core Viewpoint - The company plans to repurchase shares through a centralized bidding method, with a total repurchase amount ranging from RMB 100 million to RMB 200 million, aimed at implementing equity incentives and/or employee stock ownership plans in the future [1][3][11]. Summary by Relevant Sections Repurchase Plan Details - The repurchase amount will not be less than RMB 100 million and not exceed RMB 200 million [1][3]. - The funding sources for the repurchase will be the company's own funds and self-raised funds, with a loan commitment of up to RMB 180 million from a bank [1][10]. - The maximum repurchase price is set at RMB 25.70 per share, which is 150% of the average trading price over the previous 30 trading days [1][9]. Repurchase Execution - The repurchase will be conducted through a centralized bidding method and is expected to be completed within 12 months from the board's approval [2][5]. - The estimated number of shares to be repurchased ranges from approximately 389,110 shares to 778,210 shares, accounting for 0.98% to 1.96% of the total share capital [7][8]. Purpose and Impact - The repurchased shares will be used for equity incentives and/or employee stock ownership plans, enhancing investor confidence and aligning the interests of shareholders and employees [5][11]. - The company believes that the repurchase will not significantly impact its operations, financial status, or future development [11][12]. Shareholder Information - As of the board's approval date, major shareholders, including directors and actual controllers, have no plans to reduce their holdings in the next three to six months [2][13]. - The company has established a dedicated securities account for the repurchase, ensuring compliance with regulations [16].

此次规模达2亿元的员工持股计划，是泰恩康对未来发展前景充满信心的有力证明，也是公司治理结构 优化的重要一步。该计划的成功实施，有望成为驱动泰恩康实现新一轮高质量发展的新引擎。 本报讯 8月4日晚间，广东泰恩康医药股份有限公司（以下简称"泰恩康"）发布公告，董事会已审议通 过《广东泰恩康医药股份有限公司2025年员工持股计划（草案）》及其摘要，并提交股东大会审议。该 计划旨在通过建立员工与股东的利益共享机制，进一步激发团队活力，提升公司治理水平，推动企业长 期可持续发展。 此次员工持股计划的参与对象范围广泛，包括公司及控股子公司的董事（不含独立董事）、监事、高级 管理人员、核心骨干员工，以及董事会认为需要纳入的其他员工（以下简称"持有人"）。初始设立时， 总参与人数不超过150人，其中董事、监事及高级管理人员7人，其他员工不超过143人。具体参与人数 及名单将根据员工实际缴款情况动态确定，公司亦可根据认购款缴纳及员工变动情况对名单及分配比例 进行调整。在存续与锁定期安排上，计划存续期为36个月，自股东大会审议通过且最后一笔标的股票购 买完成公告日起算；标的股票锁定期为12个月，锁定期满后一次性解锁。 本员工持股 ...

Core Viewpoint - The company TianKang (301263.SZ) has announced a draft employee stock ownership plan for 2025, aiming to enhance employee engagement and align interests with shareholders [1] Summary by Relevant Sections Employee Stock Ownership Plan - The employee stock ownership plan will not exceed 4.9751 million shares, representing approximately 1.17% of the company's total share capital of 425.4975 million shares as of the announcement date [1] - The plan aims to raise a maximum of 200 million yuan, with each subscription unit priced at 1.00 yuan, and the ratio of financing to self-funding will not exceed 1:1 [1] Participants and Structure - Eligible participants include directors, supervisors, senior management, core employees, and other employees deemed necessary by the board, with an initial total of no more than 150 participants [1] - The initial group consists of 7 directors (excluding independent directors) and up to 143 other employees, with the final number and list to be determined based on actual contributions [1] Duration and Lock-up Period - The plan will have a duration of 36 months, with a lock-up period of 12 months for the acquired shares, starting from the date the plan is approved by the shareholders' meeting and the last purchase of shares is completed [1] - Upon the expiration of the lock-up period, 100% of the shares will be unlocked at once [1]

泰恩康(301263.SZ)披露2025年员工持股计划(草案)，持股计划初始设立时总人数不超过150人，其中董 事(不含独立董事)、监事、高级管理人员7人，其他员工不超过143人。员工持股计划股票来源为拟通过 二级市场购买等法律法规许可的方式获得泰恩康A股，持股规模不超过497.51万股;员工持股计划拟筹集 资金总额上限为2亿元。 本员工持股计划的存续期为36个月，所获标的股票的锁定期为12个月，自本员工持股计划草案经公司股 东大会审议通过且公司公告最后一笔标的股票购买完成之日起计算。 ...

泰恩康（301263）(301263.SZ)披露2025年员工持股计划(草案)，持股计划初始设立时总人数不超过150 人，其中董事(不含独立董事)、监事、高级管理人员7人，其他员工不超过143人。员工持股计划股票来 源为拟通过二级市场购买等法律法规许可的方式获得泰恩康A股，持股规模不超过497.51万股;员工持股 计划拟筹集资金总额上限为2亿元。 本员工持股计划的存续期为36个月，所获标的股票的锁定期为12个月，自本员工持股计划草案经公司股 东大会审议通过且公司公告最后一笔标的股票购买完成之日起计算。 ...

Core Points - The company held the first meeting of the 2025 Employee Stock Ownership Plan (ESOP) on August 1, 2025, with full attendance of 45 participants representing 19,731,300 shares, which is 100% of the total shares in the plan excluding reserved shares [1] - Five directors and senior management voluntarily waived their rights to attend, propose, and vote at the meeting, resulting in an effective voting share total of 15,058,800 shares [1] Group 1 - The meeting followed the procedures outlined in the company's ESOP management regulations and approved the establishment of a management committee for the ESOP, which will oversee daily management and represent shareholders [2] - The management committee consists of three members, with a term aligned with the duration of the ESOP [2] - The voting results for the establishment of the management committee showed unanimous support with 15,058,800 shares in favor [2] Group 2 - The meeting also elected three members to the management committee, who do not hold positions in the controlling shareholder or related entities, ensuring no conflicts of interest [3] - The committee members elected were Zhu Dansha, Zhao Yuyue, and Ding Annie, with Zhu Dansha appointed as the committee chair [3] - The voting results for the election of committee members were also unanimous, with 15,058,800 shares in favor [3] Group 3 - The meeting authorized the management committee to handle various matters related to the ESOP, including convening meetings, managing daily operations, and representing shareholders in exercising their rights [4] - The committee is responsible for managing the plan's assets, including cash and stock, and making decisions regarding the distribution of benefits and handling of shares [4] - The authorization is effective from the date of the meeting until the termination of the ESOP [4]

Group 1 - The company held the first meeting of the 2025 Employee Stock Ownership Plan (ESOP) on August 1, 2025, with 160 attendees representing 28,784,962.74 shares, accounting for 100% of the voting rights [1][2] - The meeting approved the establishment of a management committee for the ESOP to oversee its implementation and protect the rights of the holders [2][3] - The committee consists of three members, elected unanimously, and will serve for the duration of the ESOP [3][4] Group 2 - The management committee is authorized to handle various matters related to the ESOP, including convening meetings, supervising daily management, and exercising shareholder rights [4][5] - The ESOP has successfully completed the non-trading transfer of 3,662,209 shares, which represents 3.05% of the company's total share capital [10][11] - The total amount raised for the ESOP is 28,784,962.74 yuan, with 160 participants, and all funds have been fully paid [10][12] Group 3 - The ESOP shares will unlock in two phases, with 50% unlocking after 12 months and the remaining 50% after 24 months [11] - The ESOP holders include seven directors and senior management, but they have not signed any agreements for concerted action [12] - The company will continue to monitor the progress of the ESOP and fulfill its disclosure obligations as required [12]